EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006

Research output: Book/ReportReportResearchpeer-review

Standard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.

European Food Safety Authority, 2011.

Research output: Book/ReportReportResearchpeer-review

Harvard

Publication, EFSA & Tetens, I 2011, EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2288

APA

Publication, EFSA., & Tetens, I. (2011). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2288

Vancouver

Publication EFSA, Tetens I. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006. European Food Safety Authority, 2011. https://doi.org/10.2903/j.efsa.2011.2288

Author

Publication, EFSA ; Tetens, Inge. / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006. European Food Safety Authority, 2011.

Bibtex

@book{4350c94b5b884cdd84986e06e35e184f,
title = "EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006",
abstract = "Following an application from CSL - Centro Sperimentale del Latte S.p.A., submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora”. The scope of the application was proposed to fall under a health claim referring to children{\textquoteright}s development and health. The food constituent that is the subject of the health claim, a combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), has not been sufficiently characterised. The claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as proposed by the applicant, is children from 3 months to 14 years old. No evidence has been provided by the applicant to establish that the claimed effect, “beneficial modulation of the intestinal microflora”, is a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of the food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect related to “beneficial modulation of the intestinal microflora”. {\textcopyright} European Food Safety Authority, 2011",
author = "EFSA Publication and Inge Tetens",
year = "2011",
doi = "10.2903/j.efsa.2011.2288",
language = "English",
publisher = "European Food Safety Authority",

}

RIS

TY - RPRT

T1 - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006

AU - Publication, EFSA

AU - Tetens, Inge

PY - 2011

Y1 - 2011

N2 - Following an application from CSL - Centro Sperimentale del Latte S.p.A., submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora”. The scope of the application was proposed to fall under a health claim referring to children’s development and health. The food constituent that is the subject of the health claim, a combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), has not been sufficiently characterised. The claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as proposed by the applicant, is children from 3 months to 14 years old. No evidence has been provided by the applicant to establish that the claimed effect, “beneficial modulation of the intestinal microflora”, is a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of the food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect related to “beneficial modulation of the intestinal microflora”. © European Food Safety Authority, 2011

AB - Following an application from CSL - Centro Sperimentale del Latte S.p.A., submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora”. The scope of the application was proposed to fall under a health claim referring to children’s development and health. The food constituent that is the subject of the health claim, a combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), has not been sufficiently characterised. The claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as proposed by the applicant, is children from 3 months to 14 years old. No evidence has been provided by the applicant to establish that the claimed effect, “beneficial modulation of the intestinal microflora”, is a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of the food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect related to “beneficial modulation of the intestinal microflora”. © European Food Safety Authority, 2011

U2 - 10.2903/j.efsa.2011.2288

DO - 10.2903/j.efsa.2011.2288

M3 - Report

BT - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006

PB - European Food Safety Authority

ER -

ID: 208962787